biostudies-literatureButler CCMedical Research CouncilNational Institute for Health Research (NIHR)Wellcome Trust281-293https://www.ebi.ac.uk/biostudies/studies/S-EPMC9779781biostudies-literatureUnknown401(10373)<h4>Background</h4>The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.<h4>Methods</h4>PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older-or aged 18 years or older with relevant comorbidities-and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive Lancet (London, England)Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.PMC9779781CL-2009-13-006NF-SI-0616-10103NIHR-INF-2784NIHR203799NIHR202402MR/M008665/1216421/Z/19/ZMR/W015560/1NIHR203701CL-2016-17-007NIHR300105G1001128MC_UU_00004/04NIHR135366CL-2022-13-005NF-SI-0611-10273Wilson PNguyen-Van-Tam JSMort SPatel AAgyeman AAAllcock DStanding JFAhmed TOgundapo OFrost EPoonian SLittle PShah DWoods SOkeke HAhmed HBenedict OEHart NDGbinigie OAThalasselis CButler MPatel KHayward GRichardson SLowe DMChalk JNally RLester NMurphy DSaville BRAndersson MFox RRahman NMGranier SDanson RBreuer JBateman CDickson JFisher SCoates MLee RSoni YHobbs FDRLunn JHood KSheikh ACheng ZIrving GKennard JMathukia MDavies JCHutchinson SSidhu BSBird NWong MPatel MGLown MLavallee LButler DMcKenna MLaw TSehdev SRichards DBGhosh SAllen Jvan Hecke OCarson-Stevens AMorton SGoodman ADorward JJani BDPrasad VMwandigha LPrasad RImlach MButler CCWingfield DEvans PSingh IPANORAMIC Trial Collaborative GroupEngamba SHussain IDhasmana DBeltran-Martinez AFitzgerald MSafa AGilkar IRoyal SNdukauba CMadden TAHowell ASaunders CTRaymundo-Wood IPenfold RWooding NGaunt RLewis DThomas NPBBrennan LKrasucki CPopoola OUstianowski ABerry NSPetrou SPng MEMarion JFrancis NGalal UBarrett SOgburn ECureton LZafar Ade Kare-Silver NRazzaq OHolmes JJacobsen NRutter HWoodall MNJHarris VKnox KMoore PHadley EDobson MDetry MAYongblah FYong JBrown JBurns GKhoo SSevenoaks TMackintosh CIPora AShort VKhan UYu LMBenysek MfalseMolnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.<h4>Background</h4>The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.<h4>Methods</h4>PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older-or aged 18 years or older with relevant comorbidities-and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 2023-01-01T00:00:00Z2023 Jan2026-03-17T16:16:32.69Z2025-02-19T00:47:42.829ZS-EPMC97797813656676110.1016/S0140-6736(22)02597-1